-
Report details
-
8
Figures
-
9
Tables
-
1: Executive Summary
-
COVID-19 Testing Developments
-
Clinical Lab Situation: Volume Returns
-
No Slowing in PCR Demand
-
Large Number of Authorizations
-
Entry of Antigen Tests
-
Entry of Combo Flu Tests
-
COVID-19 Testing Market
-
Vaccines
-
Telehealth
-
2: COVD-19 Molecular Diagnostics
-
Large Number of Approvals
-
Entry of Antigen Tests
-
Test Authorized by FDA
-
Despite Choices, U.S. Labs Continue to Favor a Few Vendors
-
Other Results - Demand Remains High, Staff Shortages
-
COVID-19 Market: Molecular, Antigen and Antibody
-
COVID-19 Molecular Testing Developments
-
COVID Driving LDT Market
-
CMS Seeks to Spur Speed of Results by Cutting Fees for Slower Labs
-
Urgent care Centers Earn Over $400M from COVID-19 testing
-
Test for COVID-19 Severity vs. Detection
-
Market Forecast
-
Product Developments
-
NIH, BARDA award $98.35M in COVID-19 Contracts
-
New COVID NGS Test
-
Cue secures DOD Grant for COVID-19 tests
-
Beckman Coulter COVID-19 IgM assay
-
GenMark Multiplex test
-
Biocept reaches COVID-19 testing milestone
-
LabCorp nabs EUA for new COVID-19 molecular test
-
FDA issues EUA for OralDNA's oral rinse COVID-19 test
-
LDT s and COVID-19
-
LDTs Supported by AACC, AMP
-
3: Antigen Testing for COVID-19
-
Introduction
-
Trends
-
Serial Testing Potentially Increases Value
-
Large Numbers of Similar Products
-
Unique and Proprietary Technologies
-
FDA’s Template for Antigen Test EUAs Gives Guidance
-
Korean Companies Active in Market
-
WHO’s Activities and Recommendations in Antigen Testing
-
FIND Recommendations and Challenges
-
NIH RADx Programs
-
Vendor Moves
-
BD Veritor
-
Quidel EUA for Sofia 2 Combo flu, COVID-19 test
-
Abbott Laboratories BinaxNOW
-
Qiagen ACTIVE Anti-SARS
-
Roche to Launch Lab-based Antigen Test
-
FDA Recent Antigen Test Warning
-
4. Telehealth
-
RPM Market Performance
-
Company Results
-
COMPANY RESULTS
-
Abbott
-
American Well (Amwell)
-
Ascom Holding AG
-
Bright.md
-
Doctor On Demand
-
Eko Devices
-
G Medical Innovations Holding Ltd.
-
General Devices
-
Glooko
-
Masimo
-
Medtronic
-
OSI Systems
-
Philips - Koninklijke Philips N.V. (Royal Philips)
-
Teladoc Health
-
Thinklabs
-
TytoCare
-
5: COVID-19 and Life Science Research
-
Status of Clinical Labs
-
Life Science Instruments Market
-
COVID-19 Research and Publications
-
Shining a Spotlight in a Challenged Market: Research Antibodies for COVID-19…
-
Life Science Tools Market Considerations
-
6: Vaccines
-
Front-Runner in Development
-
How Willing are U.S. adults to accept a COVID-19 vaccine?
-
Universal Coronavirus Vaccines?
-
Moderna gets nod from EMA to submit marketing authorization
-
Passive Vaccines with Mabs may be Effective for COVID-19
-
Antibodies for passive vaccination
-
Vaccine Development
-
Who Will Get a Vaccine First?
|
COVID-19 Update: Molecular Diagnostics, Antigen Tests, Vaccines, Remote Patient Monitoring, Clinical Labs, Life Science Labs
5 Nov 2020
COVID-19 continues to be a dominant issue for healthcare systems worldwide and in the United States. Kalorama Information has covered the fields of molecular diagnostics, immunoassays, vaccines and telehealth. These all find themselves both sought-after and challenged during the current COVID-19 crisis. This report provides trending developments, company announcements and analysis from the Kalorama analysis team on the fast-breaking events in the COVID-19 epidemic.
Page Count: 84
Table of Contents
-
1: Executive Summary
-
COVID-19 Testing Developments
-
Clinical Lab Situation: Volume Returns
-
No Slowing in PCR Demand
-
Large Number of Authorizations
-
Entry of Antigen Tests
-
Entry of Combo Flu Tests
-
COVID-19 Testing Market
-
Vaccines
-
Telehealth
-
2: COVD-19 Molecular Diagnostics
-
Large Number of Approvals
-
Entry of Antigen Tests
-
Test Authorized by FDA
-
Despite Choices, U.S. Labs Continue to Favor a Few Vendors
-
Other Results - Demand Remains High, Staff Shortages
-
COVID-19 Market: Molecular, Antigen and Antibody
-
COVID-19 Molecular Testing Developments
-
COVID Driving LDT Market
-
CMS Seeks to Spur Speed of Results by Cutting Fees for Slower Labs
-
Urgent care Centers Earn Over $400M from COVID-19 testing
-
Test for COVID-19 Severity vs. Detection
-
Market Forecast
-
Product Developments
-
NIH, BARDA award $98.35M in COVID-19 Contracts
-
New COVID NGS Test
-
Cue secures DOD Grant for COVID-19 tests
-
Beckman Coulter COVID-19 IgM assay
-
GenMark Multiplex test
-
Biocept reaches COVID-19 testing milestone
-
LabCorp nabs EUA for new COVID-19 molecular test
-
FDA issues EUA for OralDNA's oral rinse COVID-19 test
-
LDT s and COVID-19
-
LDTs Supported by AACC, AMP
-
3: Antigen Testing for COVID-19
-
Introduction
-
Trends
-
Serial Testing Potentially Increases Value
-
Large Numbers of Similar Products
-
Unique and Proprietary Technologies
-
FDA’s Template for Antigen Test EUAs Gives Guidance
-
Korean Companies Active in Market
-
WHO’s Activities and Recommendations in Antigen Testing
-
FIND Recommendations and Challenges
-
NIH RADx Programs
-
Vendor Moves
-
BD Veritor
-
Quidel EUA for Sofia 2 Combo flu, COVID-19 test
-
Abbott Laboratories BinaxNOW
-
Qiagen ACTIVE Anti-SARS
-
Roche to Launch Lab-based Antigen Test
-
FDA Recent Antigen Test Warning
-
4. Telehealth
-
RPM Market Performance
-
Company Results
-
COMPANY RESULTS
-
Abbott
-
American Well (Amwell)
-
Ascom Holding AG
-
Bright.md
-
Doctor On Demand
-
Eko Devices
-
G Medical Innovations Holding Ltd.
-
General Devices
-
Glooko
-
Masimo
-
Medtronic
-
OSI Systems
-
Philips - Koninklijke Philips N.V. (Royal Philips)
-
Teladoc Health
-
Thinklabs
-
TytoCare
-
5: COVID-19 and Life Science Research
-
Status of Clinical Labs
-
Life Science Instruments Market
-
COVID-19 Research and Publications
-
Shining a Spotlight in a Challenged Market: Research Antibodies for COVID-19 Therapeutic Development
-
Life Science Tools Market Considerations
-
6: Vaccines
-
Front-Runner in Development
-
How Willing are U.S. adults to accept a COVID-19 vaccine?
-
Universal Coronavirus Vaccines?
-
Moderna gets nod from EMA to submit marketing authorization
-
Passive Vaccines with Mabs may be Effective for COVID-19
-
Antibodies for passive vaccination
-
Vaccine Development
-
Who Will Get a Vaccine First?
|
The current COVID-19 crisis affecting the United States and the world has caused hundreds of thousands of deaths and countless economic costs. This has brought forth an array of solutions that could contribute to detecting, containing and possibly treating the disease. Kalorama Information has covered the fields of molecular diagnostics, vaccines and telehealth for decades. These important industries, already growing in revenues and number of competitors, now find themselves part of the current crisis. Kalorama COVID-19 Update provides trending developments, company announcements and analysis from the Kalorama analysis team on fast-breaking events in the COVID-19 pandemic.
More information about this product
Other Users Also Viewed
26 Aug 2020
What is the Size of IVD Market Segments? Who’s Winning? Who’s Merged? Who’s Launched Game-Changing Products?
One book definitively answers these questions, from a publisher that is focused on in vitro diagnostics. Now in its 13th edition, this…
|
